The p53 pathway is often dysregulated in GBM; according to The Cancer Genome Atlas (2013), investigations have shown changes in the ARF-MDM2-p53 axis in up to 94.1% of GBM-derived cell lines and about 84% of cases (55). This evidence concerns the gene CDKN2A and glioblastoma.